A Fertile Partnership: City Fertility and Cha Medical Group
20213
post-template-default,single,single-post,postid-20213,single-format-standard,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode-title-hidden,transparent_content,qode-theme-ver-18.2,qode-theme-bridge,disabled_footer_bottom,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.5,vc_responsive

A Fertile Partnership: City Fertility and Cha Medical Group

In early 2018, one of Australia’s leading fertility and IVF providers City Fertility joined forces with Korea’s CHA Medical Group – a leading healthcare operator and a premier global leader in fertility and women’s health, and the Singapore Medical Group – one of Southeast Asia’s largest multi-disciplinary specialist clinic groups.

Now nearly two years on, Adnan Catakovic, CEO, City Fertility, reflects on the benefits of the alliance saying it has not only allowed for the further expansion of City Fertility’s capabilities, but also enhanced its continual focus on delivering clinical excellence and world-class results for their patients.

CHA Medical Group (CHA) is one of the oldest and largest private healthcare groups in Korea and Asia’s premier name in women’s health, maternity care and reproductive medicine, with more than 9,000 deliveries and approximately 30,000 IVF cases annually.

Enhanced capabilities

Mr Catakovic said City Fertility immediately benefited from joining one of the world’s largest fertility networks with unique access to CHA’s globally renowned clinical, technological, operational and R&D expertise.

“The partnership has allowed City Fertility to incorporate the latest state-of-the-art equipment, systems and facility technologies into our laboratories to further optimise the carefully controlled environment necessary for the best IVF success rates,” Mr Catakovic said.

“At the same time, we are also leveraging CHA and SMG’s long history of patient-centric care to provide a truly differentiated experience in the Australian marketplace,” he said.

Research outcomes

City Fertility is also working towards strengthening its focus on engaging in cutting-edge research with universities in Australia and abroad for the benefit of its patients, with CHA actively contributing its proprietary expertise, relationships and established R&D capabilities. This proactive research on fertility, reproductive medicine and genetics, aims to help continually increasing the chance of pregnancy for their patients.

CHA’s fertility and research centres are renowned for a number of world-first achievements including the world’s first development of the vitrification method of oocyte cryopreservation (i.e. egg freezing), the now standard method for freezing eggs.

More accessible

City Fertility is also working closely with CHA-SMG to selectively expand into new markets both domestic and international.

Its specialised services like Rainbow Fertility, Sperm and Egg Donors Australia, Chill Egg Freeze and its pre-implantation genetic screening (PGS) platform will continue as an important part of their services for patients, said Mr Catakovic.

www.cityfertility.com.au